LT-02 (Lipid Therapeutics/Dr Falk) is a modified-release formulation of phosphatidylcholine that is in Phase III development for the treatment of ulcerative colitis. The therapy is designed to improve the function of the intestinal mucosal barrier, which is impaired in ulcerative colitis patients. Phosphatidylcholine is an essential component of the intestinal mucosal barrier, and patients with ulcerative colitis have low intrinsic mucus phosphatidylcholine content, which results in the diminished function of the hydrophobic barrier in the intestinal mucus. This enables colonic bacteria to permeate the barrier, causing an immune response that leads to inflammation and ulceration.
Dr Falk and Lipid Therapeutics are seeking to position LT-02 (phosphatidylcholine; Lipid Therapeutics/Dr Falk) as both a first-line therapy for maintaining remission of mildly to moderately active ulcerative colitis and as a second-line therapy for inducing remission of mildly to moderately active ulcerative colitis. This treatment flexibility will enable LT-02 to target high patient numbers, which means greater sales potential. However, it will be forced to compete with many long-established and often cheaper therapies. Datamonitor Healthcare believes LT-02 would be in a better position to compete with branded and generic corticosteroids if a direct comparison were made in a clinical trial, with the hope that demonstrating enhanced safety of LT-02 compared to corticosteroids might convince some payers and gastroenterologists to choose the new therapy, even if it is more expensive.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 LT-02 : Inflammatory bowel disease
LIST OF FIGURES
8 Figure 1: LT-02 for ulcerative colitis – SWOT analysis
9 Figure 2: Datamonitor Healthcare drug assessment of LT-02 in ulcerative colitis
10 Figure 3: Datamonitor Healthcare drug assessment of LT-02 in ulcerative colitis
LIST OF TABLES
4 Table 1: LT-02 drug profile
7 Table 2: Ongoing pivotal trials of LT-02 in ulcerative colitis
8 Table 3: Results of the Phase II trial of LT-02 in ulcerative colitis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.